Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadazolid versus vancomycin for Clostridioides difficile-associated diarrhea
NL-OMON44362Phase 3Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing Cadazolid with Vancomycin (2 arms). Primary endpoint: Clinical cure. Started Sep 2015; status: active, not recruiting.
02
Drugs
cadazolidvancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on NL-OMON44362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44362.